To compare how much the blood inflammatory markers are reduced in psoriasis patients after giving Methotrexate treatment in one group and Methotrexate-Metformin combination treatment in the other group
- Conditions
- Health Condition 1: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2023/10/059175
- Lead Sponsor
- Saveetha Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with both psoriasis vulgaris and metabolic syndrome between the ages of 18 and 70 years consenting to be a part of the study
2. Patients with chronic plaque psoriasis
3. Patients with active disease
4. Patients who are currently not on any systemic treatment
5. Patients are nonalcoholic; liver and kidney function tests are normal
1. Patients not willing to be a part of the study
2. Patients not consenting for biopsy or blood test
3. Patients diagnosed with conditions other than psoriasis
4. Patient is pregnant or lactating
5. Patient has been using systemic drugs to treat psoriasis—such as cyclosporine, retinoid, or immunologic therapy—for one month or more
6. Patient has acute or chronic infection
7. Contraindication to use metformin and methotrexate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method